|
|
|
|
| LEADER |
03058nam a22004935i 4500 |
| 001 |
978-81-322-2607-9 |
| 003 |
DE-He213 |
| 005 |
20160121141615.0 |
| 007 |
cr nn 008mamaa |
| 008 |
160120s2016 ii | s |||| 0|eng d |
| 020 |
|
|
|a 9788132226079
|9 978-81-322-2607-9
|
| 024 |
7 |
|
|a 10.1007/978-81-322-2607-9
|2 doi
|
| 040 |
|
|
|d GrThAP
|
| 050 |
|
4 |
|a R895-920
|
| 072 |
|
7 |
|a MMN
|2 bicssc
|
| 072 |
|
7 |
|a MED080000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.07548
|2 23
|
| 100 |
1 |
|
|a Knapp, F. F. (Russ).
|e author.
|
| 245 |
1 |
0 |
|a Radiopharmaceuticals for Therapy
|h [electronic resource] /
|c by F. F. (Russ) Knapp, Ashutosh Dash.
|
| 250 |
|
|
|a 1st ed. 2016.
|
| 264 |
|
1 |
|a New Delhi :
|b Springer India :
|b Imprint: Springer,
|c 2016.
|
| 300 |
|
|
|a XXIV, 347 p. 157 illus., 72 illus. in color.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 520 |
|
|
|a This book provides detailed information on therapeutic radiopharmaceuticals and discusses emerging technologies which have potential for broad clinical implementation. Recent advances in molecular biology, radiopharmaceutical chemistry and radioisotope production have stimulated a new era for the use of radiopharmaceuticals for targeted radionuclide therapy (TRT). Emerging clinical trials include use of peptides and monoclonal antibodies radiolabeled with therapeutic radionuclides for cancer therapy. In addition, small molecules are used for the treatment of chronic diseases such as metastatic bone pain palliation and radiation synovectomy of inflammatory joints. In the interventional arena, therapy of primary and metastatic liver cancer and arterial restenosis following angioplasty of both the coronary and peripheral arteries are being explored. Reactor and accelerator production of therapeutic radioisotopes is also integrated into these discussions. The development and use of radiopharmaceutical targeting characteristics required for treatment of specific disease processes and how these are implemented for radiopharmaceutical design strategies are also described. Radiopharmaceuticals for Therapy will benefit audiences in nuclear medicine and radionuclide therapy and will thus prove an invaluable source of up-to-date information for students, radiopharmaceutical scientists and professionals working in the radiopharmacy and nuclear medicine specialties.
|
| 650 |
|
0 |
|a Medicine.
|
| 650 |
|
0 |
|a Nuclear medicine.
|
| 650 |
|
0 |
|a Endocrinology.
|
| 650 |
|
0 |
|a Oncology.
|
| 650 |
|
0 |
|a Pharmacotherapy.
|
| 650 |
1 |
4 |
|a Medicine & Public Health.
|
| 650 |
2 |
4 |
|a Nuclear Medicine.
|
| 650 |
2 |
4 |
|a Pharmacotherapy.
|
| 650 |
2 |
4 |
|a Oncology.
|
| 650 |
2 |
4 |
|a Endocrinology.
|
| 700 |
1 |
|
|a Dash, Ashutosh.
|e author.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9788132226062
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1007/978-81-322-2607-9
|z Full Text via HEAL-Link
|
| 912 |
|
|
|a ZDB-2-SME
|
| 950 |
|
|
|a Medicine (Springer-11650)
|
